Aequus Pharmaceuticals Statistics

Total Valuation

Aequus Pharmaceuticals has a market cap or net worth of CAD 663,172. The enterprise value is 7.18 million.

Market Cap	663,172
Enterprise Value	7.18M

Important Dates

The next estimated earnings date is Thursday, May 1, 2025.

Earnings Date	May 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Aequus Pharmaceuticals has 132.63 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	132.63M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	14.96%
Owned by Institutions (%)	n/a
Float	112.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.61
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.68
EV / Sales	17.37
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 0.05

Current Ratio	0.05
Quick Ratio	0.01
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-10.85

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-153.07%
Return on Capital (ROIC)	-378.98%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	12
Asset Turnover	0.41
Inventory Turnover	1.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -80.00% in the last 52 weeks. The beta is -0.02, so Aequus Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y)	-0.02
52-Week Price Change	-80.00%
50-Day Moving Average	0.01
200-Day Moving Average	0.02
Relative Strength Index (RSI)	36.73
Average Volume (20 Days)	60,629

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aequus Pharmaceuticals had revenue of CAD 413,165 and -2.68 million in losses. Loss per share was -0.02.

Revenue	413,165
Gross Profit	220,830
Operating Income	-2.49M
Pretax Income	-2.68M
Net Income	-2.68M
EBITDA	-2.48M
EBIT	-2.49M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 25,408 in cash and 6.54 million in debt, giving a net cash position of -6.51 million or -0.05 per share.

Cash & Cash Equivalents	25,408
Total Debt	6.54M
Net Cash	-6.51M
Net Cash Per Share	-0.05
Equity (Book Value)	-6.22M
Book Value Per Share	-0.05
Working Capital	-6.28M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-2.48M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	53.45%
Operating Margin	-601.60%
Pretax Margin	-647.62%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Aequus Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	-403.46%
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Aequus Pharmaceuticals has an Altman Z-Score of -74.11. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-74.11
Piotroski F-Score	n/a